ClinicalTrials.gg
Active, not recruitingNCT06993233CitylightsUpdated Oct 19, 2026

A Study With CIT-013 in HS Patients

A Phase 2 interventional study of CIT-013 high dose and CIT-013 medium dose in Hidradenitis Suppurativa (HS), sponsored by Citryll BV. Active, not recruiting at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Citryll BV · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies in Hidradenitis Suppurativa with a site in Poland — 6 open to participants now, 18 under way, 11 of them phase 3. Hidradenitis Suppurativa · Poland.

Enrollment
36th of 45
108 · median 234
Started
2025
with 12 others
Phase 2
21 of 45
3 open now
Primary completion
2027-04
later than 10 of 17 live
Registered
36th of 45
by date

Among the 45 studies in Hidradenitis Suppurativa with a site in Poland, this one is the 36th largest by enrollment, is one of 13 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 36th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

6 of the 45 studies in Hidradenitis Suppurativa with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hidradenitis Suppurativa with a site in Poland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:

Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS.

Participants will:

Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

03

Conditions studied

  • Hidradenitis Suppurativa (HS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants with HS of more than 6 months duration,
  • 18 years of age at screening visit,
  • Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III (according to Hurley classification system),
  • A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment/randomization,
  • Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a to oral antibiotics for treatment of their HS,
  • Total draining tunnel count less than 20

Exclusion criteria

Exclusion Criteria:

- Participants for whom an approved therapy with demonstrated clinical benefit is indicated, available and expected to be tolerated, OR choose to proceed with standard of care treatment options over the IP (after being appropriately informed of the treatment options, risks, and benefits).

Any current and/or recurrent skin condition in the treatment area other than HS,

  • Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline
  • Prior treatment with any of the following medications before baseline:

    1. Any other systemic therapy for HS (28 days before baseline)
    2. Any IV anti-infective therapy (14 days before baseline)
  • History of with exception of non-melanoma skin cancer that has been excised and cured,
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    CIT-013 high dose

    6 SC injections with CIT-013 high dose

    Drug: CIT-013 high dose

  • Experimental
    CIT-013 medium dose

    6 SC injections with CIT-013 medium dose

    Drug: CIT-013 medium dose

  • Placebo comparator
    Placebo

    6 SC injections with placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with HiSCR75 on CIT 013 versus placebo

    Time frame: week 12

Secondary outcomes

  1. Incidence of TEAEs as assessed by CTCAE

    Time frame: week 12

  2. Maximum Plasma Concentration of CIT-013 before doses

    Time frame: 4, 6, 10 and 12 weeks

07

Study locations

28 sites
  • CA-01
    Barrie, Canada
  • CA-05
    Calgary, Canada
  • CA-02
    London, Canada
  • CA-04
    Newmarket, Canada
  • CA-03
    Winnipeg, Canada
  • DE-06
    Bad Bentheim, Germany
  • DE-01
    Bochum, Germany
  • DE-04
    Dresden, Germany
  • DE-02
    Frankfurt, Germany
  • DE-08
    Kiel, Germany
  • DE-03
    Oldenburg, Germany
  • Erasmus UMC
    Rotterdam, Netherlands
  • PL-06
    Bialystok, Poland
  • PL-08
    Gdansk, Poland
  • PL-03
    Katowice, Poland
  • PL-02
    Lodz, Poland
  • PL-10
    Lodz, Poland
  • PL-09
    Poznan, Poland
  • PL-01
    Rzeszów, Poland
  • PL-05
    Wroclaw, Poland
  • ES-05
    Barcelona, Spain
  • ES-04
    Madrid, Spain
  • ES-02
    Santiago de Compostela, Spain
  • ES-03
    Seville, Spain
  • ES-01
    Valencia, Spain
  • GB-02
    Cardiff, United Kingdom
  • GB-05
    Chester, United Kingdom
  • GB-04
    London, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 18 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 28, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 19, 2026
Enrollment
96 (estimated)→108 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Active, not recruiting
    Enrollment 96 (estimated)→108 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06993233
Lead sponsor
Citryll BV
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Oct 31, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Maarten Kraan
study director · Citryll BV

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CIT-013

Start the discussion